# Kupando

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kupando

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.kupando.com
- Total disclosed funding: $27M
- Latest round: Series A (Mar 18, 2026)
- Investors on record: 7

## About

Based in Brandenburg, Germany, and founded in 2018, Kupando GmbH is a biopharmaceutical company that develops TLR 4/7 agonists that stimulate innate immunity. In March 2026, Kupando GmbH raised EUR 10 million in series A funding co-led by Remiges Ventures and LifeCare Partners, with participation from Brandenburg Kapital, High-Tech Gruenderfonds, Ventura BioMed Investors and CARMA FUND Management. The firm as of September 2022 is led by its founder and CEO, Johanna Holldack, and its Chairman, Pierre Morgon.

The biopharmaceutical company is working on the development of TLR 4/7 agonists, that targets Toll-Like Receptors (TLRs) responsible for the detection of cancer and infectious molecules, and for the subsequent activation of the innate immune system. The company’s KUP101 is the only TLR 4/7 agonist in development and consists of TLR 4 agonist and a TLR 7 agonist co-encapsulated in a liposomal formulation this compound induces a broad immune response, which will facilitate its development as an anti-tumor agent in combination with other anti-tumor modalities, or a prophylactic vaccine for infectious diseases. This provides a multitude of options for administration routes and applications in Oncology and other infectious diseases.

The company plans to utilize its March 2026 funding to fund the Phase 1b clinical study of KUP101 in advanced solid tumors and accelerate preclinical programs in infectious diseases.

## Funding rounds

- Series A, Mar 18, 2026, $12M — High-Tech Gruenderfonds, Brandenburg Kapital, Remiges Ventures, LifeCare Partners, Ventura BioMed Investors, CARMA FUND Management
- Series A, Oct 22, 2021, $15M — High-Tech Gruenderfonds, Brandenburg Kapital, Remiges Ventures, Eckenstein-Geigy-Stiftung, LifeCare Partners, Ventura BioMed Investors

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series A
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A
- Eckenstein-Geigy-Stiftung — Series A
- LifeCare Partners (https://capitalatlas.ai/funds/lifecare-partners) — Series A
- Ventura BioMed Investors (https://capitalatlas.ai/funds/ventura-biomed-investors) — Series A
- CARMA FUND Management (https://capitalatlas.ai/funds/carma-fund-management) — Series A